| Pulmonary arterial hypertension
Uptravi vs WINREVAIR
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Uptravi vs Winrevair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWinrevair has a higher rate of injection site reactions vs Uptravi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Winrevair but not Uptravi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Uptravi
Winrevair
At A Glance
Oral / IV infusion
Twice daily
Prostacyclin receptor agonist
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Starting dose 200 mcg orally twice daily; increase by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily. For moderate hepatic impairment (Child-Pugh class B), start at 200 mcg once daily and increase by 200 mcg once daily at weekly intervals. When co-administered with a moderate CYP2C8 inhibitor, reduce dosing to once daily. IV infusion (80-minute) is dosed twice daily at the corresponding tablet dose for patients temporarily unable to take oral therapy.
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Contraindications
- Hypersensitivity to selexipag or any excipient
- Concomitant use of strong CYP2C8 inhibitors (e.g., gemfibrozil)
—
Adverse Reactions
Most common (>=3%) Headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in extremity, flushing, arthralgia, rash, anemia, decreased appetite
Postmarketing Symptomatic hypotension
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Pharmacology
Selexipag is a prostacyclin receptor (IP receptor) agonist structurally distinct from prostacyclin; it is hydrolyzed by carboxylesterase 1 to an active metabolite approximately 37-fold more potent, selective for the IP receptor over other prostanoid receptors (EP1-4, DP, FP, and TP).
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Uptravi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (10/12)
Winrevair
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Uptravi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Winrevair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
Humana
Uptravi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Winrevair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Janssen CarePath Oral PAH Savings Program: UptraviCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Merck Access Co-pay Assistance: WinrevairCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UptraviView full Uptravi profile
WinrevairView full Winrevair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.